SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO
FILED PURSUANT TO RULE 13d-2(a)(1)
(Amendment No. 1)(2)
------------------------------------
PATHOGENESIS CORPORATION
------------------------
(Name of Issuer)
Common Stock, par value $.001 per share
(Title of Class of Securities)
70321E104
--------------------------------------------------
(CUSIP Number)
Stephen H. Kay, Esq.
Squadron, Ellenoff, Plesent & Sheinfeld, LLP
551 Fifth Avenue
New York, New York 10176
(212) 661-6500
(Name, address and telephone number of person
authorized to receive notices and communications)
May 10, 1999
------------------------------------
(Date of event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d- 1(g),
check the following box º_º
Note. Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See ss. 240.13d-7(b) for other
parties to whom copies are to be sent.
--------
(1) The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Exchange Act") or otherwise subject to the liabilities of that
section of the Exchange Act but shall be subject to all other provisions of the
Exchange Act (however, see the Notes).
(2) This amendment amends and restates the Statement originally filed by Fred
Wilpon on September 3, 1998 and amends and restates information from the
Statement on Schedule 13G originally filed by Marvin B. Tepper on September 3,
1998 and the Statement on Schedule 13G originally filed by Saul B. Katz on
September 3, 1998 with the Securities and Exchange Commission.
Page 1 of 14 Pages
CUSIP No. 70321E04 13D
================================================================================
1 º Name of Reporting Person/
º I.R.S. Identification No. of Above Person
º Fred Wilpon
--------------------------------------------------------------------------------
2 º Check the Appropriate Box if a Member of a Group (See Instructions) (a) º_º
º (b) º_º
--------------------------------------------------------------------------------
3 º SEC Use Only
º
--------------------------------------------------------------------------------
4 º Source of Funds (See Instructions)
º 00
--------------------------------------------------------------------------------
5 º Check if Disclosure of Legal Proceedings is Required
º Pursuant to Item 2(d) or 2(e) º_º
--------------------------------------------------------------------------------
6 º Citizenship or Place of Organization
º USA
--------------------------------------------------------------------------------
º 7 º Sole Voting Power 53,982 (all 53,982
º º shares underlying
º º exercisable options)
Number of º-----------------------------------------------------------
Shares º 8 º Shared Voting Power 819,000
Beneficially º º
Owned By º-----------------------------------------------------------
Each º 9 º Sole Dispositive Power 53,982 (all 53,982
Reporting º º shares underlying
Person º º exercisable options)
With º-----------------------------------------------------------
º 10 º Shared Dispositive Power 819,000
º º
--------------------------------------------------------------------------------
11 º Aggregate Amount Beneficially Owned By Each Reporting Person
º 872,982
º
--------------------------------------------------------------------------------
12 º Check Box if the Aggregate Amount in Row (11) excludes Certain Shares º_º
º (See Instructions)
--------------------------------------------------------------------------------
13 º Percent of Class Represented by Amount in Row (11)
º 5.3%
º
--------------------------------------------------------------------------------
14 º Type of Reporting Person
º IN
================================================================================
Page 2 of 14 Pages
CUSIP No. 70321E04 13D
================================================================================
1 º Name of Reporting Person/
º I.R.S. Identification No. of Above Person
º Marvin B. Tepper
--------------------------------------------------------------------------------
2 º Check the Appropriate Box if a Member of a Group (See Instructions) (a) º_º
º (b) º_º
--------------------------------------------------------------------------------
3 º SEC Use Only
º
--------------------------------------------------------------------------------
4 º Source of Funds (See Instructions)
º 00
--------------------------------------------------------------------------------
5 º Check if Disclosure of Legal Proceedings is Required
º Pursuant to Item 2(d) or 2(e) º_º
--------------------------------------------------------------------------------
6 º Citizenship or Place of Organization
º USA
--------------------------------------------------------------------------------
º 7 º Sole Voting Power 47,732 (all 47,732
º º shares underlying
º º exercisable options)
Number of º-----------------------------------------------------------
Shares º 8 º Shared Voting Power 800,000
Beneficially º º
Owned By º-----------------------------------------------------------
Each º 9 º Sole Dispositive Power 47,732 (all 47,732
Reporting º º exercisable options) shares underlying
Person º º exercisable options)
With º-----------------------------------------------------------
º 10 º Shared Dispositive Power 800,000
º º
--------------------------------------------------------------------------------
11 º Aggregate Amount Beneficially Owned By Each Reporting Person
º 847,732
º
--------------------------------------------------------------------------------
12 º Check Box if the Aggregate Amount in Row (11) excludes Certain Shares º_º
º (See Instructions)
--------------------------------------------------------------------------------
13 º Percent of Class Represented by Amount in Row (11)
º 5.2%
º
--------------------------------------------------------------------------------
14 º Type of Reporting Person
º IN
================================================================================
Page 3 of 14 Pages
CUSIP No. 70321E04 13D
================================================================================
1 º Name of Reporting Person/
º I.R.S. Identification No. of Above Person
º Saul B. Katz
--------------------------------------------------------------------------------
2 º Check the Appropriate Box if a Member of a Group (See Instructions) (a) º_º
º (b) º_º
--------------------------------------------------------------------------------
3 º SEC Use Only
º
--------------------------------------------------------------------------------
4 º Source of Funds (See Instructions)
º 00
--------------------------------------------------------------------------------
5 º Check if Disclosure of Legal Proceedings is Required
º Pursuant to Item 2(d) or 2(e) º_º
--------------------------------------------------------------------------------
6 º Citizenship or Place of Organization
º Delaware
--------------------------------------------------------------------------------
º 7 º Sole Voting Power 40,000
º º
Number of º-----------------------------------------------------------
Shares º 8 º Shared Voting Power 815,000
Beneficially º º
Owned By º-----------------------------------------------------------
Each º 9 º Sole Dispositive Power 40,000
Reporting º º
Person º-----------------------------------------------------------
With º 10 º Shared Dispositive Power 815,000
º º
--------------------------------------------------------------------------------
11 º Aggregate Amount Beneficially Owned By Each Reporting Person
º 855,000
º
--------------------------------------------------------------------------------
12 º Check Box if the Aggregate Amount in Row (11) excludes Certain Shares ºXº
º (See Instructions) (Excludes 30,000 shares held by Mr. Katz' adult
º children in a partnership.)
--------------------------------------------------------------------------------
13 º Percent of Class Represented by Amount in Row (11)
º 5.2%
º
--------------------------------------------------------------------------------
14 º Type of Reporting Person
º IN
================================================================================
Page 4 of 14 Pages
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Amendment No. 1)
Pursuant to Section 13(d) of the
Securities Exchange Act of 1934
in respect of
PATHOGENESIS CORPORATION
Introductory Statement
This Amendment No. 1 (this "Amendment") to the Statement on Schedule
13D (the "Statement") relates to the Common Stock, par value $.001 per share
(the "Common Stock"), of PathoGenesis Corporation, a Delaware corporation (the
"Company"). This Amendment amends and restates the Statement originally filed by
Fred Wilpon on September 3, 1998 and amends and restates information from the
Statement on Schedule 13G originally filed by Marvin B. Tepper on September 3,
1998 and the Statement on Schedule 13G originally filed by Saul B. Katz
(together with Fred Wilpon and Marvin Tepper, the "Reporting Persons") on
September 3, 1998 with the Securities and Exchange Commission ("SEC").
In May 1999, the Reporting Persons elected to jointly file this
Amendment with respect to their respective beneficial ownership of shares of
Common Stock of the Company.
Item 1. Security and Issuer.
The title of the class of equity securities to which this Statement
relates is the Common Stock of the Company. The principal executive offices of
the Company are located at 201 Elliott Avenue West, Seattle, Washington 98119.
Item 2. Identity and Background.
This Statement is being filed by the following:
Page 5 of 14 Pages
(a) Fred Wilpon, a citizen of the United States with a business
address of c/o Sterling PathoGenesis Company, 575 Fifth Avenue, New York, New
York 10017. Mr. Wilpon is President and Chief Executive Officer of the New York
Mets baseball team, co-founder of and Chairman of the Board of Sterling
Equities, Inc. (real estate developer), 575 Fifth Avenue, New York, New York
10017 ("Sterling Equities"), and co-founder of and Director of the Company.
(b) Marvin B. Tepper, a citizen of the United States with a business
address of c/o Sterling PathoGenesis Company, 575 Fifth Avenue, New York, New
York 10017. Mr. Tepper is Executive Vice President of Sterling Equities, and
co-founder of and Secretary of the Company.
(c) Saul B. Katz, a citizen of the United States with a business
address of c/o Sterling PathoGenesis Company, 575 Fifth Avenue, New York, New
York 10017. Mr. Katz is President of Sterling Equities.
During the last five years, none of the Reporting Persons has (i) been
convicted in a criminal proceeding (excluding minor traffic violations or
similar misdemeanors), or (ii) been a party to a civil proceeding of a judicial
or administrative body of competent jurisdiction a result of which it was or is
subject to a judgment, decree or final order enjoining future violations of, or
prohibiting or mandating activities subject to, federal or state securities laws
or finding any violations with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration.
800,000 shares of Common Stock are held by Sterling PathoGenesis
Company ("Sterling"), of which Mr. Wilpon is managing partner and Messrs. Tepper
and Katz are partners, and were purchased with funds from Sterling; 9,000 shares
are held jointly by Mr. Wilpon and his spouse and were purchased with personal
funds; 10,000 shares are held jointly by Mr. Wilpon and Mr. Katz and were
purchased with personal funds; 40,000 shares are held by Mr. Katz and were
purchased with personal funds; and 5,000 shares are held jointly by Mr. Katz and
his spouse and were purchased with personal funds. Mr. Wilpon was granted stock
options for 53,982 shares of Common Stock issuable upon the exercise of such
options
Page 6 of 14 Pages
and Mr. Tepper was granted stock options for 47,732 shares of Common Stock
issuable upon the exercise of such options.
Item 4. Purpose of Transaction.
The Reporting Persons purchased the Common Stock for investment.
The Reporting Persons intend to continuously review their respective
investments in the Company, and may in the future determine to (i) acquire
additional securities of the Company, through open market purchases, private
agreements or otherwise, (ii) dispose of all or a portion of the securities of
the Company owned by them, (iii) take any other available course of action,
which could involve one or more of the types of transactions or have one or more
of the results described in the next paragraph of this Item 4 or (iv) otherwise
change their investment intent. Notwithstanding anything contained herein, the
Reporting Persons specifically reserve the right to change their intentions with
respect to any or all of such matters. In reaching any decision as to their
course of action (as well as to the specific elements thereof), the Reporting
Persons currently expect that they would take into consideration a variety of
factors, including, but not limited to, the Company's financial condition,
business, operations and prospects, other developments concerning the Company,
other business opportunities available to the Reporting Persons, other
developments with respect to the business of the Reporting Persons, general
economic and industry conditions and money and securities market conditions,
including the market price of the securities of the Company.
Other than as described herein, none of the Reporting Persons have any
present plans or proposals which relate to or would result in: (a) the
acquisition by any person of additional securities of the Company or the
disposition of securities of the Company; (b) an extraordinary corporate
transaction, such as a merger, reorganization or liquidation, involving the
Company or any of its subsidiaries; (c) a sale or transfer of a material amount
of assets of the Company or any of its subsidiaries; (d) any change in the Board
of Directors or management of the Company, including any plans or proposals to
change the number or terms of directors or to fill any existing vacancies on the
Board of Directors of the Company;
Page 7 of 14 Pages
|
